1 Bad company? The pericardium microbiome in people investigated for tuberculosis

2 pericarditis in an HIV-prevalent setting

- 3
- 4 Georgina Nyawo^{1,2†}, Charissa Naidoo^{1,2†}, Benjamin G. Wu^{3,4}, Benjamin Kwok³, Jose C.
- 5 Clemente⁵, Yonghua Li³, Stephanie Minnies¹, Byron Reeve¹, Suventha Moodley^{1,2},
- 6 Thadathilankal-Jess John^{6,7}, Sumanth Karamchand⁷, Shivani Singh³, Alfonso Pecararo⁷,
- 7 Anton Doubell⁷, Charles Kyriakakis⁸, Robin Warren¹, Leopoldo N. Segal³, Grant Theron^{1,2#}
- 8 [†]Contributed equally
- 9

10 **Running title**: Pericardium microbiome in tuberculosis

11

12 Affiliations:

¹DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African

14 Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology

15 and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University,

16 Cape Town, South Africa;

17 ²African Microbiome Institute, Faculty of Medicine and Health Sciences, Stellenbosch

18 University, Cape Town, South Africa;

³Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New

20 York University School of Medicine, New York, USA;

⁴Division of Pulmonary and Critical Care, Veterans Affairs New York Harbor Healthcare

- 22 System, New York, NY, USA;
- ⁵Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,
- 24 New York, USA;
- ⁶Panorama Mediclinic, Cape Town, South Africa;
- ²⁶ ⁷Department of Medicine, Division of Cardiology, Stellenbosch University & Tygerberg
- 27 Academic Hospital, Cape Town, South Africa;
- ⁸Life Vincent Pallotti Hospital, Cape Town, South Africa.

29

30 ***Corresponding author**:

- 31 Professor Grant Theron, 2nd Floor BMRI Building, Division of Molecular Biology and Human
- 32 Genetics, Faculty of Medicine and Health Sciences, Francie Van Zijl Drive, Tygerberg, South
- 33 Africa, 7505.
- 34 E-mail: <u>gtheron@sun.ac.za</u>
- 35 Telephone: +27 21 938 9693
- 36
- 37 Keywords: pericarditis, extrapulmonary tuberculosis, microbiome, HIV

38 Abstract

Background: The microbiome likely plays a role in tuberculosis (TB) pathogenesis. We evaluated the site-of-disease microbiome and predicted metagenome in people with presumptive tuberculous pericarditis, a major cause of mortality, and explored for the first time, the interaction between its association with C-reactive protein (CRP), a potential diagnostic biomarker and the site-of-disease microbiome in extrapulmonary TB.

Methods: People with effusions requiring diagnostic pericardiocentesis (n=139) provided
background sampling controls and pericardial fluid (PF) for 16S rRNA gene sequencing
analysed using QIIME2 and PICRUSt2. Blood was collected to measure CRP.

47 **Results:** PF from people with definite (dTB, n=91), probable (pTB, n=25), and non- (nTB, 48 n=23) tuberculous pericarditis differed in β-diversity. dTBs were, vs. nTBs, Mycobacterium-, 49 Lacticigenium-, and Kocuria-enriched. Within dTBs, HIV-positives were Mycobacterium-, 50 Bifidobacterium-, Methylobacterium-, and Leptothrix-enriched vs. HIV-negatives and HIV-51 positive dTBs on ART were Mycobacterium- and Bifidobacterium-depleted vs. those not on 52 ART. Compared to nTBs, dTBs exhibited short-chain fatty acid (SCFA) and mycobacterial 53 metabolism microbial pathway enrichment. People with additional non-pericardial 54 involvement had differentially PF taxa (e.g., Mycobacterium-enrichment and Streptococcus-55 depletion associated with pulmonary infiltrates). Mycobacterium reads were in 34% (31/91), 56 8% (2/25) and 17% (4/23) of dTBs, pTBs, and nTBs, respectively. β-diversity differed 57 between patients with CRP above vs. below the median value (Pseudomonas-depleted). 58 There was no correlation between enriched taxa in dTBs and CRP.

59 **Conclusions:** PF is compositionally distinct based on TB status, HIV (and ART) status and 60 dTBs are enriched in SCFA-associated taxa. The clinical significance of these findings, 61 including mycobacterial reads in nTBs and pTBs, requires evaluation.

62 Introduction

The burden of tuberculosis (TB) is severe in sub-Saharan Africa, where HIV is frequent¹. In 2021, South Africa reported >300 000 incident TB cases and 61 000 deaths¹. About 16% of incident cases are extrapulmonary, affecting sites outside the lungs². Extrapulmonary TB (EPTB) has high fatality, especially in people living with HIV (PLHIV)³. Tuberculous pericarditis (TBP) is an especially severe manifestation, and the deadliest manifestation of EPTB, with up to 40% mortality⁴⁻⁶.

69

70 Immune responses to Mycobacterium tuberculosis complex (Mtb) involve a cascade of events that are, in part, influenced by the microbiome and their metabolites⁷⁸. For instance, 71 72 gut enrichment with specific anaerobes (Anaerostipes, Blautia, Erysipelotrichaceae) 73 independently predicts activation of host inflammatory immune pathways and active pulmonary TB compared to sick controls⁹¹⁰. In PLHIV on ART, greater microbially-derived 74 75 short chain fatty acid (SCFA; butyrate, propionate) concentrations in the lower airways independently predict incident TB¹¹. When SCFAs are added at physiological 76 77 concentrations to alveolar macrophages ex vivo, there are reductions in macrophage-78 mediated *Mtb* kill¹¹.

79

C-reactive protein (CRP) is a non-specific blood inflammatory marker for triage¹², especially in PLHIV in primary care, where it is WHO-recommended¹³. In studies where CRP was coanalysed with the microbiome, CRP negatively correlated with abundances of antiinflammatory-associated gut microbiota¹⁴ such as *Faecalibacterium*¹⁵, *Lactobacillus* and *Bifidobacterium*¹⁶. In COVID-19 patients, CRP correlated with potentially pathogenic bacteria such as *Klebsiella* spp. and *Enterococcus* spp. ¹⁷ However, the relationship between CRP and the site-of-disease microbiota in presumptive TBP has not been studied.

87

Little is known about the microbiome of the pericardial space, especially in the context of EPTB, a major cause of pericardial disease. Previous research has hinted at the influence of

microbiota on TB, making it a promising treatment avenue⁷⁻⁹. Our work showed the presence
of distinctive microbial communities at the site of disease in people with presumptive
tuberculous lymphadenitis¹⁸. Importantly, these communities differed by TB status (definite-,
probable- or non-TB) and clinical characteristics, with specific community states (i.e., *Mycobacterium*-dominated lymphotype) being associated with more severe disease¹⁸.

95

96 Together, this can aid in the identification of novel biomarkers at the microbial-host interface 97 that leads to strategies like host-directed therapies for TB prevention and treatment, 98 including in PLHIV. This could also enhance our understanding of severe inflammation in 99 EPTB, which partly contributes to its high morbidity and mortality. Understanding interactions 100 in the microbiome, together with correlations with CRP can help find meaningful networks via 101 which microbes and host interact, and this can help uncover novel associations and 102 mechanisms.

103

We therefore evaluated the site-of-disease microbiome and its predicted metagenome in people investigated for TBP (including PLHIV) as well as whether CRP as a surrogate for inflammation correlates with specific taxa. This work will help provide foundational data on the microbiome's role in TBP.

108 Methods

109 Recruitment and follow-up

110 People with presumed TB pericarditis referred to Tygerberg Academic Hospital in Cape 111 Town, South Africa for routine diagnostic investigation including pericardiocentesis were 112 recruited between 24 November 2016 and 9 April 2021. Eligible people were ≥18 years old 113 and not on TB treatment for ≥ 2 weeks. Demographic, clinical, and chest X-ray (CXR) data 114 were collected. People with TBP were managed by the overseeing clinician in line with 115 current guidelines for the management and treatment of pericardial effusions, and assessed 116 by telephonic follow-up after a minimum of 12 weeks. The study had no role in patient 117 management.

118

119 Ethics

All people provided written informed consent. The study was approved by the Stellenbosch
University Health Research and Ethical Committee (HREC, N16/04/050), Tygerberg
Academic Hospital, and the Western Cape Department of Health (WC_2016RP15_762).

123

124 Specimen collection and processing

125 Two sampling controls were collected per person: a skin swab of the sterilised puncture site 126 and a sterile saline (Ysterplaat Medical Supplies, South Africa) flush of the vascular sheath 127 prior to pericardiocentesis (background control). At least 4mL pericardial fluid (PF) was 128 collected once sufficient volumes were obtained for routine diagnostic testing. Samples were 129 stored at -80°C until batched DNA extraction. Peripheral blood was collected in serum-130 separating tubes (SST tubes; BD), and centrifuged (2054g, 10 min) within four hours of 131 collection, and serum stored at -80°C. Further details on specimen collection and 132 microbiological testing is in the **Supplementary material**.

133

134 Patient classification

135 We designated people as definite tuberculous pericarditis (dTB), probable tuberculous 136 pericarditis (pTB), or non-tuberculous pericarditis (nTB) per Table S1¹⁹. People were 137 classified as dTBs if they were positive for acid-fast bacilli by Ziehl-Neelsen smear 138 microscopy and/or had at least one MTB-positive specimen by Mycobacteria Growth 139 Indicator Tube (MGIT) 960 liquid culture (BD Diagnostics, USA), Xpert MTB/RIF (Xpert; 140 Cepheid, USA) and/or Xpert MTB/RIF Ultra (Ultra; Cepheid, USA). pTBs did not meet dTB 141 criteria, had no alternative diagnosis, and were empirically prescribed TB therapy. nTBs had 142 no microbiological evidence of TB and were not placed on treatment.

143

144 Laboratory procedures

The PureLink Microbiome DNA Purification Kit (Invitrogen, USA) was used for PF, skin swabs and, for efficiency, 1 in 5 background samples. The 16S rRNA gene V4 hypervariable region (150 bp read length, paired-end) was amplified and underwent Illumina MiSeq sequencing¹¹. Further detail is in the **Supplementary Material**. CRP was measured in biobanked serum using the Cobas High-Sensitivity Immunoturbidimetric Assay (Roche Diagnostics Limited, Burgess Hill, UK) per the manufacturer's <u>instructions</u>.

151

152 Microbiota analyses

153 <u>Pre-processing</u>: Sequences were pre-processed using QIIME (version 2020.8)²⁰ and 154 DADA2²¹. Amplicon sequence variants (ASVs) were assigned at 99% similarity against 155 representative sequences in Greengenes (version 13.8)²² with zero abundance taxa 156 removed.

157Taxonomic analyses: α- and β-diversities were calculated using vegan (v2.6-4)23.158Differential taxa and pathway abundance analyses used DESeq2 (v1.22.2)24 with Benjamini–159Hochberg (BH) multiple testing correction after feature tables were pruned (genera not seen160>5 times in ≥1% of samples removed)25. CRP was categorised as high or low if the161concentration readout was above or below the median for the people included in that

162 analysis. Detailed methods for identifying potential contaminants and clustering analysis are

163 in the **Supplementary Material.**

164 <u>Functional pathway analyses</u>: Phylogenetic Investigation of Communities by 165 Reconstruction of Unobserved States (PICRUSt2; v.2.1.3-b)²⁶ was used for metagenomic 166 inference with default parameters (picrust2_pipeline.py) and metabolic function predictions 167 based on MetaCyc²⁷.

168 <u>Correlation analysis with CRP and microbiome:</u> Only sequence data with paired CRP 169 measurements were included. Microbial relative abundances were correlated with CRP 170 measurements using Correlations Under the Influence (CUTIE)²⁸.

171

172 Statistical analyses

173 Analyses used GraphPad Prism (v7; GraphPad Software, USA), STATA (v16; StataCorp, 174 USA) and R (v4.2; R Core Team). Medians with interguartile ranges (IQRs) were reported 175 for continuous variables, and the number and percentage were reported for categorical variables. Non-parametric tests (microbiome data are not normally distributed²⁹) included the 176 177 Mann-Whitney or Wilcoxon signed-rank test for unpaired and paired comparisons involving 178 two groups, Kruskal-Wallis or Friedman tests for unpaired and paired comparisons involving 179 ≥2 groups, and Spearman's Rho for correlation analyses. Permutational multivariate analysis 180 of variance (PERMANOVA) was computed with 999 permutations for β -diversity, and R^2 181 used to measure variation explained by a variable. The Benjamini-Hochberg procedure was 182 used to correct for multiple comparisons by controlling the false discovery rate (FDR)²⁵. 183 Adjusted p-values of <0.2 and <0.05 were considered significant for taxa and pathways. respectively³⁰. More information is in the **Supplementary Methods**. 184

185 Results

186 Cohort characteristics

Our cohort was comprised of 91 (65%), 25 (18%) and 23 (17%) dTBs, pTBs, and nTBs, respectively (**Table 1**). Compared to nTBs, dTBs were more likely to have HIV, cough, weight loss, be on medication (other than TB medication) and, in their PF, have lower albumin but higher adenosine deaminase (ADA), lactate dehydrogenase (LDH), and unstimulated interferon-gamma (uIFN-γ) concentrations. pTBs were more likely than nTBs to have HIV, previous TB, and TB symptoms and, in PF, lower albumin and higher ADA and uIFN-γ concentrations.

194

195 Pericardial fluid shares few taxa with skin and background controls

PF α-diversity was lower than background and skin. PF β-diversity differences occurred with Mycobacterium- (vs. skin and background) and *Streptococcus*-enrichment (vs. skin only) (**Figure S1A-D**). None of the top four potentially contaminating taxa identified appeared in differential analyses (**Figures S2-3**, <u>additional table</u>).

200

201 Mycobacterium and other potential opportunistic pathogens are enriched in dTBs

202 Differences by TB status: We did not detect α -diversity differences (Figure 2A). β -203 diversity differed between dTBs and pTBs, as well as pTBs vs. nTBs (PERMANOVA 204 p=0.020 and 0.003, respectively, **Figure 2B**), but not between dTBs and nTBs. dTBs were 205 Mycobacterium-, Lacticigenium-, and Kocuria-enriched vs. nTBs (Figure 2C), and 206 Mycobacterium-, Lacticigenium- and Caulobacter-enriched and Streptococcus-depleted vs. 207 pTBs (Figure 2D). pTBs were Streptococcus- (vs. dTBs) and Novosphingobium-enriched vs. 208 nTBs (Figure 2D-E), and more phylogenetically dissimilar to each other. dTBs were the 209 most phylogenetically similar to each other followed by nTBs (Figure S4).

210 <u>Grouping pTBs with dTBs or nTBs</u>: When pTBs were grouped with dTBs or nTBs,
 211 there were no α- or β-diversity differences vs. nTBs or dTBs, respectively (Figure S5A-D).

212 dTBs were Mycobacterium- and Lacticigenium-enriched vs. nTBs regardless of with whom

213 pTBs were grouped (Figure S5E-F).

214 <u>16S rRNA gene sequencing correlates with diagnostic results:</u> Mycobacterial reads 215 occurred in more dTBs than pTBs [34% (31/91) vs. 8% (2/25), p=0.011] but did not reach 216 significance when dTBs were compared to nTBs [17% (4/23), p=0.181] (**Figure 2F, Figure** 217 **S6**). Mycobacterial reads inversely correlated with PCR (r=-0.361, p<0.012; **Figure S7A**)

- and culture measures of mycobacterial load (r=-0.484, *p*<0.001; **Figure S7B**).
- 219

220 Bifidobacterium enrichment is associated with HIV

Although α- and β-diversity did not differ by HIV status (Figure S8A-B), PLHIV were
 Mycobacterium-enriched vs. HIV-negatives (Figure S8C).

223 <u>Comparisons by HIV status within different TB groups:</u> No α- and β-diversity 224 differences by HIV status occurred in dTBs or pTBs (**Table S2**). In dTBs, HIV-positives were 225 *Methylobacterium-*, *Bifidobacterium-*, and *Leptothrix*-enriched vs. HIV-negatives (**Figure** 226 **S8D**). nTBs were not compared by HIV status due to a small sample size (n=2 HIV-227 positives).

228 Comparisons by TB status within people of the same HIV status: In HIV-positives, α -229 diversity was similar by TB status (Figure 3A) but β -diversity differed (*p*=0.038; Figure 3B) 230 and dTBs were Mycobacterium-, Bifidobacterium-, and Leptothrix-enriched vs. pTBs (Figure 231 **3C**). α - and β -diversities were similar between HIV-positives with high vs. low CD4 counts 232 (dichotomised at median value, data not shown), where those with lower counts were 233 *Mycobacterium*-enriched vs. people with higher counts (**Figure S9A-B**). In HIV-negatives, α -234 and β -diversities were similar between TB groups (Figure 3D-E) and taxonomic differences 235 were only observed between dTBs vs. pTBs, with dTBs Kocuria-, Halomonas-, and 236 Gilvimarinus-enriched (Figure 3F).

237 <u>Comparisons by ART status in PLHIV:</u> A third of PLHIV were on ART (**Table 1**). α-238 Diversity was similar by ART status, but β-diversity differed (**Table S2**). Those on ART were

239 Streptococcus-enriched and Mycobacterium- and Bifidobacterium-depleted vs. those not on

ART (Figure S9C) and conclusions were similar when restricted to dTBs (Figure S9D).

241

242 Chest abnormalities associated with the microbiome.

We evaluated microbiome differences by CXR results (Table 1) and found no α-diversity
differences. However, β-diversity differed in people with vs. without pulmonary infiltrates
(PIs; Table S2), with people with PIs *Mycobacterium*-enriched and *Streptococcus*-depleted
(Figure 4A). β-diversity also differed in people with or without pleural effusions (PEs) (Table
S2), where people with PEs were *Streptococcus*- and *Pseudomonas*-enriched and *Brachymonas*-depleted (Figure 4B).

249

250 People with definite TBP are enriched in SCFA metabolic pathways.

251 Compared to nTBs, dTBs were enriched with SCFA metabolism (L-lysine fermentation to 252 acetate and butanoate), aromatic compound degradation (cinnamate and 3-253 hydroxycinnamate degradation to 2-oxopent-4-enoate), and mycobacterial metabolism 254 (superpathway of mycolyl-arabinogalactan-peptidoglycan complex biosynthesis) pathways 255 (Figure 5). Amongst dTBs, HIV-positives were depleted in biosynthesis pathways [GDP-D-256 glycero-α-D-manno-heptose biosynthesis, peptidoglycan biosynthesis V (β-lactam 257 resistance) and superpathway of geranylgeranyl diphosphate biosynthesis II (via MEP)] 258 compared to HIV-negatives (Figure S10). Comparisons involving pTBs are in Figures S11-

- 259 **S12.**
- 260

261 The association between CRP and the microbiome

262 <u>Microbial composition differed with Pseudomonas depleted in high vs. low CRP</u>

CRP concentrations did not differ by TB status [median 137.30 (IQR 75.30 - 176.30) ng/mL
in dTBs vs. 95.96 (IQR 45.25 - 173.70) ng/mL in nTBs] (Figure 6A) nor correlated with *Mycobacterium* reads (Figure 6B-C). People with above median CRP concentrations
[median 125.4 (IQR70.83 - 176.7) ng/mL] had, vs. those below the median, no α-diversity

- 267 differences (Figure 6D) but different β-diversity (Figure 6E), with *Pseudomonas*-depletion
- 268 (Figure 6F). These differences were similar when restricted to people of a specific TB
- 269 (Table 2) or HIV status (Figures S13-14), with a few additional taxa differentially enriched.
- 270 The top three taxa enriched in dTBs (Mycobacterium, Lacticigenium, Kocuria) did not
- correlate with CRP levels (p-values of 0.523, 0.260, and 0.999, respectively).

272 Discussion

273 Our key findings are that 1) compared to PF from people without TBP, PF from people with 274 TBP differs both in terms of β -diversity and the relative abundance of specific taxa, including 275 those other than Mycobacterium (Lacticigenium, Kocuria, and Weeksella), 2) HIV is 276 associated with the differential abundance of Mycobacterium overall, and within dTBs, 277 Bifidobacterium is associated with proxies of more severe disease (HIV-positivity and, in 278 PLHIV, no ART), and 3) taxonomic differences between dTBs and nTBs manifest in different 279 functional capacities, including enrichment of SCFA production pathways. Furthermore, 4) 280 the PF microbiome is associated with distinctive clinical and chest imaging characteristics 281 and 5) many people with dTB do not have PF Mycobacterium reads whereas some people 282 without dTB have Mycobacterium reads, 6) CRP did not differ by TB status or HIV status, 283 and α -diversity was similar by CRP status, however, β -diversity differed, with *Pseudomonas* 284 enrichment in people with low (vs. high) CRP. This is the first characterisations of the site-of-285 disease microbiome in people with pericarditis, specifically in a high TB HIV-endemic setting.

286

dTBs were enriched in several taxa in addition to *Mycobacterium*. These include *Kocuria*, a skin commensal that causes an infection of the heart e.g., native valve endocarditis, albeit rarely³¹, and *Weeksella* which can also cause serious bacterial infections like bacteraemia, and spontaneous bacterial peritonitis³². The relevance of these taxa in TBP requires further investigation.

292

Mycobacterium was enriched in PLHIV compared to people without HIV. Furthermore, *Bifidobacterium* was associated with clinical features characteristic of severe disease (HIVpositivity and, in those with HIV, no ART and lower CD4 counts. *Bifidobacterium*, while commonly considered a beneficial, immunomodulatory gut commensal³³, has been described as either depleted^{9 34} or enriched^{35 36} in people with pulmonary TB compared to symptomatic controls. However, our findings are consistent with the latter. *Bifidobacterium*

can act opportunistically, causing bacteraemia in immunocompromised people and those
 with a damaged intestinal barrier³⁷.

301

Similar to previous work involving people with different forms of TB (i.e., pulmonary TB and TB lymphadenitis³⁸), people with TBP were enriched in SCFA-producing bacteria (e.g., *Lacticigenium* produces acetic and lactic acid) and pathways (*L-lysine fermentation to acetate and butanoate*, amino acid and carbohydrate metabolism butyrate precursor pathways)^{39 40}. dTBs also had elevated PF concentrations of LDH, a marker of tissue damage, however we acknowledge that it could include microbially-derived LDH. Lactate metabolism is also important for *Mtb* growth⁴¹

309

Furthermore, HIV-positive dTBs not on ART are, in addition to *Mycobacterium*, enriched in *Bifidobacterium*, a known producer of lactate which itself is also an intermediate metabolite
of the butyrate biosynthetic pathway^{42 43}. Butyrate suppresses protective host responses
(IFN-γ and IL-17A) to *Mtb.* Future studies should evaluate whether enhanced site-of-disease
SCFA production correlates with both local and peripheral inflammation.

315

316 Pericarditis is often associated with pulmonary parenchymal disease. Notably, the PF 317 microbiome was associated with a greater probability of chest imaging characteristics where 318 individuals with PI showed distinct PF β-diversity compared to those without, characterized 319 by increased Mycobacterium (likely resulting from more direct contact with the route of 320 infection and site of pulmonary disease) and reduced Streptococcus. Similarly, individuals 321 with pleural effusion exhibited different PF β -diversity compared to those without, with higher 322 levels of Streptococcus and lower levels of Brachymonas. Pulmonary infiltrates are commonly observed in radiological imaging of individuals with pulmonary TB⁴⁴, while pleural 323 324 effusions are predominantly caused by TB in developing countries⁴⁵. Consequently, 325 obtaining sputum cultures and Xpert tests is crucial in suspected cases of TBP, even when 326 parenchymal involvement is not evident. Furthermore, the co-existence of these features

327 may reflect the TB route from the lungs to the heart, and what taxa might accompany that 328 spread.

329

330 People within each TB group had Mtb DNA detected. The reasons for this are likely 331 multifaceted: primarily due to technical methodological limitations (metagenomic sequencing 332 would have more discriminatory power for species within Mycobacteria) but could also be 333 due to TB exposure, past infection, TB disease at another anatomical site, or cross-334 contamination. It is important to note that 66% of dTBs did not show Mycobacterium 335 readings, likely due to the limited sensitivity of 16S rRNA sequencing for detecting this 336 genus, whose cells often lyse and release DNA inefficiently and may be biased against by 337 conventional sequencing approaches (a "mycobacteriome" approach could be used to study 338 mycobacterial diversity further)⁴⁶.

339

340 CRP is a commonly studied biomarker in TB, and during active TB infection, CRP levels 341 tend to be elevated due to the body's immune response to the mycobacterial infection⁴⁷. 342 Similarly, CRP levels can be elevated in individuals with HIV because HIV infection is 343 associated with chronic inflammation and immune activation, particularly in those with advanced disease or opportunistic infections⁴⁸⁻⁵⁰. However, in our study, unlike previously 344 reported studies⁵¹⁻⁵³, the level of CRP, appears to not be influenced by the presence of 345 346 active TB in TBP. Despite this, the median CRP value in our TBP cohort 125.4 (70.83 -176.70) ng/mL exceeded the diagnostic threshold ⁵⁴ for TB diagnosis. This observation can 347 348 be attributed to the fact our study only included people that were suspected to have TPB, 349 leading to the presence of specific clinical symptoms and some form of the disease, 350 regardless of whether it was TB or another condition. As a result, this could have contributed 351 to the elevated CRP levels to some extent. Notably, we observed a depletion of 352 Pseudomonas in presumptive TBP people with high CRP compared to those with low CRP, 353 similar to a report of an adverse relationship between sputum genus richness and CRP in bronchiectasis^{55 56}. 354

355

356 The study has strengths and limitations. DNA-based sequencing was employed to analyze 357 microbial communities, and alternative methods like culturomics, metagenomics, or 358 metatranscriptomics may yield different results. Furthermore, as our study was nested within 359 TB care at our hospital, our study data were influenced by limitations in routinely available 360 data (e.g., unknown ART duration); however, this allowed us to recruit a high number of 361 people. We also did background sampling and sequencing to detect potential cross-362 contamination of our low biomass fluid (PF), which allowed us to confirm that none of the 363 discriminatory taxa identified in our analyses likely resulted from contamination. The study 364 used a relaxed FDR-adjusted p-value threshold of 0.2 to identify various taxa, prioritizing 365 hypothesis generation. This threshold was chosen as lower thresholds did not yield 366 significant taxa, underscoring the need for broader exploration. We do not know which 367 microbes are driving the high CRP in TB, however, this study was not designed to 368 investigate this, and further studies would be required. We acknowledge the non-specificity 369 of CRP as a general marker of inflammation. Finally, this study is a cross-sectional study, so 370 it's unable to establish temporal relationships.

371

In summary, the microbiomes of people with TBP (including those co-infected with HIV) are different to people without TBP and characterised by enriched *Mycobacterium* and other potentially immunomodulatory bacteria (*Bifidobacterium, Lacticigenium*). Further research is needed to define these mechanistic relationships (e.g., through murine models), including how the microbiota is altered by treatment and its association, if any, with clinical outcomes. This will provide insights into the development of effective host-directed therapies for TBP.

378 Funding

379 This work and authors were supported by the European & Developing Countries Clinical 380 Trials Partnership (EDCTP; project numbers SF1041, TMA2019CDF-2738-ESKAPE-TB), 381 National Research Foundation, South African Medical Research Council (SAMRC), Harry 382 Crossley Foundation and Stellenbosch University Faculty of Health Sciences. We also 383 acknowledge funding from Veterans Affairs (IK2BX005309-01A2) and the National Institutes 384 of Health under award number KL2TR001446, and CHEST Foundation Research Grant in 385 Chronic Obstructive Pulmonary Disease. CCN and GT acknowledge funding from the 386 National Institutes of Health under award numbers K43TW012302 and R01Al136894. GRN 387 acknowledges funding from L'Oréal-UNESCO For Women in Science Sub-Saharan Africa 388 Young Talents Award, and the International Rising Talents Award. The content is the solely 389 the responsibility of the authors and does not necessarily represent the official views of the 390 funders.

391

392 Acknowledgments

The authors thank all study participants and CLIME staff, especially Sr Ruth Wilson.
Computations were performed using facilities provided by the University of Cape Town's
ICTS High Performance Computing team: <u>hpc.uct.ac.za.</u>

396

397 Conflict of Interest

398 The other authors each declare no competing interests.

399

400 References

401 1. World Health Organization. Global Tuberculosis Report 2022. Geneva, Switzerland, 2022.

402 2. Gupta RK, Lawn SD, Bekker L-G, et al. Impact of human immunodeficiency virus and

- 403 CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South
- 404 Africa. The international journal of tuberculosis and lung disease 2013;17(8):1014-22.

- 405 3. Leeds IL, Magee MJ, Kurbatova EV, et al. Site of extrapulmonary tuberculosis is
 406 associated with HIV infection. 2012;55(1):75-81.
- 407 4. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. *Circulation* 408 2005;112(23):3608-16.
- 409 5. Noubiap JJ, Agbor VN, Ndoadoumgue AL, et al. Epidemiology of pericardial diseases in
- 410 Africa: a systematic scoping review. *Heart* 2019;105(3):180-88.
- 6. Mayosi BM, Wiysonge CS, Ntsekhe M, et al. Mortality in patients treated for tuberculous
 pericarditis in sub-Saharan Africa. *S Afr Med J* 2008;98(1):36-40.
- 413 7. Somboro AM, Diallo D, Holl JL, Maiga M. The role of the microbiome in inflammation
 414 during tuberculosis. *EBioMedicine* 2021;68
- 415 8. Mori G, Morrison M, Blumenthal A. Microbiome-immune interactions in tuberculosis. *PLoS*
- 416 *Pathogens* 2021;17(4):e1009377.
- 417 9. Naidoo CC, Nyawo GR, Sulaiman I, et al. Anaerobe-enriched gut microbiota predicts pro-
- 418 inflammatory responses in pulmonary tuberculosis. *EBioMedicine* 2021;67:103374.
- 419 10. Naidoo CC, Nyawo GR, Wu BG, et al. The microbiome and tuberculosis: state of the art,
- 420 potential applications, and defining the clinical research agenda. *Lancet Respir Med*421 2019;7(10):892-906. doi: 10.1016/S2213-2600(18)30501-0 [published Online First:
- 421 2019,7(10).092-900. doi: 10.1010/32213-2000(10)30301-0 [published Offinite Thist. 422 20190322]
- 423 11. Segal LN, Clemente JC, Li Y, et al. Anaerobic Bacterial Fermentation Products Increase
- 424 Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients. Cell host & microbe

425 2017;21(4):530-37 e4. doi: 10.1016/j.chom.2017.03.003

- 426 12. Du Clos TW. Function of C-reactive protein. *Annals of medicine* 2000;32(4):274-78.
- 427 13. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2:
 428 screening-systematic screening for tuberculosis disease. Geneva, Switzerland: World
 429 Health Organization 2021.
- 430 14. Ma W, Nguyen LH, Song M, et al. Dietary fiber intake, the gut microbiome, and chronic
 431 systemic inflammation in a cohort of adult men. *Genome medicine* 2021;13(1):102.

- 432 15. Furet J-P, Kong L-C, Tap J, et al. Differential adaptation of human gut microbiota to
- 433 bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation
- 434 markers. *Diabetes* 2010;59(12):3049-57.
- 435 16. Rajkumar H, Mahmood N, Kumar M, et al. Effect of probiotic (VSL# 3) and omega-3 on
- 436 lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight
- 437 adults: a randomized, controlled trial. *Mediators Inflamm* 2014;2014
- 438 17. Petakh P, Kobyliak N, Kamyshnyi A. Gut microbiota in patients with COVID-19 and type
- 439 2 diabetes: A culture-based method. *Frontiers in Cellular and Infection Microbiology*440 2023;13:108.
- 18. Nyawo GR, Naidoo CC, Wu B, et al. More than Mycobacterium tuberculosis: site-ofdisease microbial communities, and their functional and clinical profiles in tuberculous
 lymphadenitis. *Thorax* 2023;78(3):297-308.
- 19. Reuter H, Burgess L, van Vuuren W, Doubell A. Diagnosing tuberculous pericarditis.
- 445 QJM: An International Journal of Medicine 2006;99(12):827-39. doi:
 446 10.1093/gjmed/hcl123
- 20. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible
- 448 microbiome data science using QIIME 2. *Nature biotechnology* 2019;37(8):852-57.
- 21. Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: high-resolution sample inference
 from Illumina amplicon data. *Nature methods* 2016;13(7):581-83.
- 451 22. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with
 452 explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *The ISME*453 *journal* 2012;6(3):610.
- 454 23. Dixon P. VEGAN, a package of R functions for community ecology. *Journal of*455 *Vegetation Science* 2003;14(6):927-30.
- 456 24. McMurdie PJ, Holmes S. Waste not, want not: why rarefying microbiome data is
 457 inadmissible. *PLoS computational biology* 2014;10(4)
- 458 25. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false
- discovery rate controlling procedures. *Bioinformatics* 2003;19(3):368-75.

- 460 26. Douglas GM, Maffei VJ, Zaneveld J, et al. PICRUSt2: An improved and customizable
- 461 approach for metagenome inference. *BioRxiv* 2020:672295.
- 462 27. Caspi R, Altman T, Billington R, et al. The MetaCyc database of metabolic pathways and
- 463 enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res
- 464 2014;42(D1):D459-D71.
- 465 28. Bu K, Wallach DS, Wilson Z, et al. Identifying correlations driven by influential
 466 observations in large datasets. *Briefings in Bioinformatics* 2022;23(1):bbab482.
- 467 29. Estaki M, Jiang L, Bokulich NA, et al. QIIME 2 Enables Comprehensive End-to-End
- 468 Analysis of Diverse Microbiome Data and Comparative Studies with Publicly Available

469 Data. *Current protocols in bioinformatics* 2020;70(1):e100.

- 470 30. Seumois G, Zapardiel-Gonzalo J, White B, et al. Transcriptional profiling of Th2 cells
- 471 identifies pathogenic features associated with asthma. *The Journal of Immunology*472 2016;197(2):655-64.
- 473 31. Kandi V, Palange P, Vaish R, et al. Emerging bacterial infection: identification and
 474 clinical significance of Kocuria species. *Cureus* 2016;8(8)
- 475 32. Campbell IM, Congdon M, Capucilli PS, Fox WW. A Not So Common Infection in an
- 476 Extremely Low-Birth-Weight Infant. *Clinical Pediatrics* 2020;59(11):1040-42.
- 477 33. Lokesh D, Parkesh R, Kammara R. Bifidobacterium adolescentis is intrinsically resistant
 478 to antitubercular drugs. *Scientific reports* 2018;8(1):11897.
- 479 34. Baral T, Kurian SJ, Thomas L, et al. Impact of tuberculosis disease on human gut
 480 microbiota: a systematic review. *Expert Review of Anti-infective Therapy* 2023(just481 accepted)
- 482 35. Khaliq A, Ravindran R, Afzal S, et al. Gut microbiome dysbiosis and correlation with
 483 blood biomarkers in active-tuberculosis in endemic setting. *PloS one*484 2021;16(1):e0245534.
- 36. Wang Y, Deng Y, Liu N, et al. Alterations in the Gut Microbiome of Individuals With
 Tuberculosis of Different Disease States. *Frontiers in Cellular and Infection Microbiology*2022:328.

- 488 37. Esaiassen E, Hjerde E, Cavanagh JP, et al. Bifidobacterium bacteremia: clinical
 489 characteristics and a genomic approach to assess pathogenicity. *Journal of clinical*490 *microbiology* 2017;55(7):2234-48.
- 38. Nyawo GG, Naidoo CC, Wu B, et al. More than Mycobacterium tuberculosis: specific
 site-of-disease microbial communities, functional capacities, and their distinct clinical
- 493 profiles in tuberculous lymphadenitis. *bioRxiv* 2022
- 494 39. Schillinger U, Endo A. Minor genera of the Carnobacteriaceae: Allofustis, Alloiococcus,
- 495 Atopobacter, Atopococcus, Atopostipes, Bavariicoccus, Desemzia, Dolosigranulum,
- 496 Granulicatella, Isobaculum and Lacticigenium. Lactic Acid Bacteria: Biodiversity and
- 497 *Taxonomy* 2014:159-70.
- 498 40. lino T, Suzuki K-i, Harayama S. Lacticigenium naphtae gen. nov., sp. nov., a halotolerant
 499 and motile lactic acid bacterium isolated from crude oil. *International journal of systematic*500 *and evolutionary microbiology* 2009;59(4):775-80.
- 501 41. Billig S, Schneefeld M, Huber C, et al. Lactate oxidation facilitates growth of 502 Mycobacterium tuberculosis in human macrophages. *Scientific reports* 2017;7(1):1-12.
- 503 42. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host
- physiology: short-chain fatty acids as key bacterial metabolites. *Cell* 2016;165(6):133245.
- 43. Baxter NT, Schmidt AW, Venkataraman A, et al. Dynamics of human gut microbiota and
 short-chain fatty acids in response to dietary interventions with three fermentable fibers. *mBio* 2019;10(1):e02566-18.
- 44. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical
 review. *Tuberculosis* 2011;91(6):497-509.
- 511 45. Light RW. Update on tuberculous pleural effusion. *Respirology* 2010;15(3):451-58.

46. Thornton CS, Mellett M, Jarand J, et al. The respiratory microbiome and nontuberculous
mycobacteria: an emerging concern in human health. *European Respiratory Review*2021;30(160)

515	47. Wilson D, Badri M, Maartens G. Performance of serum C-reactive protein as a screening
516	test for smear-negative tuberculosis in an ambulatory high HIV prevalence population.
517	PLoS ONE 2011;6(1):e15248.

- 48. Sage E, Noursadeghi M, Evans H, et al. Prognostic value of C-reactive protein in HIV-
- 519 infected patients with Pneumocystis jirovecii pneumonia. International journal of STD &
- 520 *AIDS* 2010;21(4):288-92.
- 49. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and
 hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with
 increased risk of AIDS or death. *Journal of Infectious Diseases* 2011;203(11):1637-46.
- 524 50. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum C-
- reactive protein for screening for HIV-associated tuberculosis. *The International journal of tuberculosis and lung disease* 2013;17(5):636-43.
- 527 51. Ciccacci F, Floridia M, Bernardini R, et al. Plasma levels of CRP, neopterin and IP-10 in
- 528 HIV-infected individuals with and without pulmonary tuberculosis. *Journal of Clinical* 529 *Tuberculosis and Other Mycobacterial Diseases* 2019;16:100107.
- 530 52. Liu H, Zheng R, Wang P, et al. IL-37 confers protection against mycobacterial infection
 531 involving suppressing inflammation and modulating T cell activation. *PLoS ONE*532 2017;12(1):e0169922.
- 533 53. Steingart KR, Schiller I, Horne DJ, et al. Xpert® MTB/RIF assay for pulmonary 534 tuberculosis and rifampicin resistance in adults. *Cochrane database of systematic* 535 *reviews* 2014(1)
- 536 54. Yoon C, Semitala FC, Atuhumuza E, et al. Point-of-care C-reactive protein-based
 537 tuberculosis screening for people living with HIV: a diagnostic accuracy study. *The Lancet*538 *Infectious Diseases* 2017;17(12):1285-92.
- 539 55. Rogers GB, Zain NMM, Bruce KD, et al. A novel microbiota stratification system predicts
 540 future exacerbations in bronchiectasis. *Annals of the American Thoracic Society*541 2014;11(4):496-503.

- 542 56. Richardson H, Dicker AJ, Barclay H, Chalmers JD. The microbiome in bronchiectasis.
- 543 European Respiratory Review 2019;28(153)
- 544

545 Data availability

- 546 Data and code will be made available upon publication. Other supporting data are available
- 547 from the corresponding author (GT) on reasonable request.

548 Table 1: Demographic and clinical characteristics of people with presumptive TB 549 pericarditis. dTBs were more likely to have HIV, cough, weigh less, be using non-TB 550 medications and, in PF, have lower albumin concentrations and higher ADA, LDH, and 551 uIFN-y concentrations than nTBs. pTBs were more likely to have HIV, previous TB, more self-reported symptoms, have lower albumin concentration, and have higher 552 553 ADA and uIFN-y fluid concentration, than nTBs. dTBs were less likely to already be on 554 treatment at recruitment (< 2 weeks) compared to pTBs. Data are n/N (%) or median 555 (IQR).

	Pe	ople with pres	p-value				
	Total (n=139)	dTB (n=91)	pTB (n=25)	nTB (n=23)	dTB vs. pTB	dTB vs. nTB	pTB vs. nTB
Age, years	37 (31, 48)	40 (31, 48)	34 (31, 46)	37 (31, 58)	0.910	0.563	0.485
Sex (Female)	59/139 (42)	37/91 (41)	10/25 (40)	12/23 (52)	>0.999	0.450	0.580
Current tobacco smoker	30/138 (22)	17/90 (19)	6/25 (24)	7/23 (30)	0.780	0.360	0.860
Previous tobacco smoker	29/108 (27)	19/73 (26)	7/19 (37)	3/16 (19)	0.370	0.950	0.420
Clinical characteristics:							
HIV	75/139 (54)	53/91 (58)	20/25 (80)	2/23 (9)	0.046	<0.0001	<0.0001
On ART	26/73 (37)	18/53 (34)	7/18 (39)	1/2 (50)	0.930	>0.999	>0.999
CD4 count, cells/µl	158 (54, 319)	151 (49, 328)	208 (97, 339)	106 (36, 176)	>0.999	>0.999	0.971
Previous TB	31/136 (23)	21/88 (24)	9/25 (36)	1/23 (4)	0.339	0.072	0.019
Self-reported symptoms:							
Cough	76/132 (58)	52/85 (61)	16/24 (67)	8/23 (35)	0.801	0.043	0.058
Fever	52/131 (40)	35/85 (41)	12/23 (52)	5/23 (22)	0.480	0.142	0.067
Night sweats	68/133 (51)	45/86 (52)	15/24 (63)	8/23 (35)	0.510	0.210	0.110
Weight loss	85/134 (63)	60/87 (69)	17/24 (71)	8/23 (35)	>0.999	0.006	0.029
Chest X-ray results:							
Cardiomegaly	93/139 (67)	61/91 (67)	17/25 (68)	15/23 (65)	>0.999	>0.999	>0.999
Pulmonary infiltrates	31/139 (22)	23/91 (25)	4/25 (16)	4/23 (17)	0.480	0.600	>0.999
Hilar lymphadenopathy	11/139 (8)	7/91 (8)	(8) 2/25 (8) 2/23 (9) >0.9		>0.999	>0.999	>0.999
Miliary pattern	7/139 (5)	6/91 (7)	1/25 (4)	0/23 (0)	0.990	0.460	>0.999
Pleural effusion	88/139 (63)	60/91 (66)	16/25 (64)	12/23 (52)	>0.999	0.330	0.590
Pericardial tamponade	47/127 (37)	29/81 (36)	9/23 (39)	9/23 (39)	0.960	0.960	>0.999
Treatment history:							
Current TB treatment (<2 weeks)	21/139 (15)	12/91 (13)	9/25 (36)	0/23 (0)	0.020	0.144	0.005
No TB treatment	118/139 (85)	79/91 (87)	16/25 (64)	23/23 (100)	0.020	0.144	0.005
Other medications	58/129 (45)	33/83 (40)	9/23 (39)	16/23 (70)	>0.999	0.210	0.076
Non-TB antibiotic use within 1 year	21/125 (17)	12/80 (15)	7/24 (29)	2/17 (12)	0.200	>0.999	0.350
Current non-TB antibiotic use	17/21 (81)	10/12 (83)	5/7 (71)	2/2 (100)	0.980	>0.999	>0.999
Total volume aspirated (mL) 700 (500		670 (500, 915)	720 (500, 1000)	750 (400, 1050)	>0.999	>0.999	>0.999
Fluid cytochemistry:							
ADA (U/L)	48 (26, 67)	51 (34, 68)	50 (38, 65)	50 (38, 65) 16 (11, 33)		0.001	0.016
Protein (g/L)	58 (50, 65)	58 (49, 64)	61 (55, 67)	60 (50, 64)	>0.999	>0.999	>0.999
LDH (g/L)	696 (424, 1440)	840 (451, 1440)	645 (541, 1490)	408 (181, 842)	>0.999	0.016	0.132

Albumin (U/L)	22 (16, 26)	21 (16, 25)	23 (19, 26)	28 (25, 30)	>0.999	0.010	0.126
uIFN-γ (pg/mL)	803 (3, 2510)	1150 (165, 2590)	885 (4, 2810)	28 (0, 5)	>0.999	<0.0001	<0.0001
Blood CRP (mg/L)*	125 (71, 177)	137 (75, 176)	136 (93, 202)	96 (45, 174)	>0.999	>0.999	>0.999
Mortality	24 (18)	14/88 (16)	4/24 (17)	6/22 (27)	>0.999	0.350	0.610
56 *For CRP, paired samples w	ere available from	112/139 parti	cipants (72/91	dTB; 20/25	pTB and 20)/23 nTB). N	lissing data

557 Current tobacco smoker (n=1), Previous tobacco smoker (n=31), ART status (n=2), Previous TB (n=3), Self-reported symptoms
558 (n=8), Other medications (n=10), Non-TB antibiotic use within 1 year (n=14). Bold indicates statistical significance (P < 0.05).
559 Abbreviations: ADA: adenosine deaminase; ART: antiretroviral therapy; CRP: C-reactive protein; dTB: definite tuberculous

560 pericarditis; IQR: interquartile range; LDH: lactate dehydrogenase; nTB: non-tuberculous pericarditis; pTB: probable

561 tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis; and uIFN-γ: unstimulated interferon gamma

- 562 Table 2: CRP levels do not affect microbiome α-diversity, but influence β-diversity in
- 563 people with presumptive TBP. α-diversity remained consistent regardless of CRP
- 564 concentration, while significant differences in β-diversity were observed, indicating

565 distinct microbial compositions between the two groups.

	Overall (n=139)			dTB (n=91)			pTB (n=25)			nTB (n=23)		
High vs. low CRP	α-diversity	β-diversity			β-diversity			β-diversity			β-diversity	
		p- value	R ² value	α-diversity	p-value	R ² value	α-diversity	p-value	R ² value	α-diversity	p-value	R ² value
All participants	0.982	0.015	0.02723	0.982	0.013	0.02723	0.2265	0.527	0.0461	0.5967	0.3333	0.04407
Within HIV-positives	0.8932	0.059	0.02537	0.5028	0.05	0.03891	0.6744	0.826	0.04857	0.3173	-	-
Within HIV-negatives	0.1432	0.526	0.01987	0.2282	0.719	0.03419	0.1213	0.3333	0.36901	0.6911	0.668	0.04903

Bold indicates statistical significance (P < 0.05). Abbreviations: CRP: C-reactive protein; dTB: definite tuberculous pericarditis; nTB: non-tuberculous pericarditis; pTB: probable tuberculous pericarditis; TB: tuberculous.

566 Figure legends

567

Figure 1: Study flow chart. Pericardial fluid, skin and background controls were collected
from 140 presumptive TBP people. dTBs: definite tuberculous pericarditis; nTBs: nontuberculous pericarditis; pTBs: probable tuberculous pericarditis; Smear: Smear microscopy;
MGIT960 Culture: Mycobacteria Growth Indicator Tube 960 liquid culture; Xpert: Xpert
MTB/RIF; Ultra: Xpert MTB/RIF Ultra.

573

574 Figure 2: dTBs have a distinct microbiome enriched in Mycobacterium and other 575 potential opportunistic pathogens. (A) Although α -diversity, which measures species 576 diversity, was similar across the three groups, (B) β -diversity, which measures differences in 577 microbial composition, differed significantly between PF microbiota of pTBs vs. dTBs and 578 pTBs vs. nTBs. (C) dTBs vs. nTBs were Mycobacterium-, Lacticigenium- and Kocuria-579 enriched, and Streptococcus-depleted. (D) dTBs vs. pTBs were Mycobacterium-, 580 Lacticigenium-, and Caulobacter-enriched and Streptococcus-depleted. (E) pTBs vs. nTBs 581 were Novosphingobium- and Streptococcus-enriched (red dotted line represents adjusted p-582 value=0.2; circle size represents relative abundance; taxa identified as possible 583 contaminants are shown in grey). (F) Genus-level average relative abundances of top taxa 584 differentiating between TB groups. dTB: definite tuberculous pericarditis; nTB: non-585 tuberculous pericarditis; PF: pericardial fluid; pTB: probable tuberculous pericarditis; TB: 586 tuberculosis; TBP: tuberculous pericarditis.

587

Figure 3: *Bifidobacterium* enrichment is associated with *Mycobacterium* and HIV positivity in TBP. In PLHIV, (A) α -diversity did not differ by TB status, (B) however, β diversity did, (C) where HIV-positive dTBs were *Mycobacterium-, Bifidobacterium-,* and *Leptothrix*-enriched, and *Streptococcus*-depleted compared to HIV-positive pTBs. In people without HIV, both (D) α -diversity and (F) β -diversity did not differ by TB status, and HIVnegative dTBs were *Mycobacterium, Caulobacter,* and *Weeksella*-enriched, and

594 *Streptococcus*-depleted compared to HIV-negative pTBs (red dotted line represents adjusted 595 *p*-value=0.2; circle size represents relative abundance; taxa identified as possible 596 contaminants are shown in grey). dTB: definite tuberculous pericarditis; HIV+: HIV-positive; 597 HIV-: HIV-negative; nTB: non- tuberculous pericarditis; PF: pericardial fluid; pTB: probable 598 tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis

599

600 Figure 4: Correlations between imaging and clinical characteristics and the PF 601 microbiota. Pulmonary infiltrates (PI) and pleural effusions (PE) are assotiated with PF 602 microbiome. Compared to patients without PI, (A) presumptive TBPs with a PI were 603 Mycobacterium-enriched and Lacticigenium- and Streptococcus-depleted, whilst (B) 604 compared to patients without PE, presumptive TBP people with PE were Streptococcus- and 605 Pseudomonas-enriched, and Brachymonas-depleted (red dotted line represents adjusted p-606 value=0.2; circle size represents relative abundance; taxa identified as possible 607 contaminants are shown in grey). dTB: definite tuberculous pericarditis; PF: pericardial 608 fluid; PE: pleural effusions; PI: pulmonary infiltrates; pTB: probable tuberculous pericarditis; 609 TB: tuberculosis; TBP: tuberculous pericarditis

610

Figure 5: Inferred functional content shows enrichment of SCFA metabolic pathways in the PF of TBP. PF in dTBs infer a disctint functional capacity, including an enrichment of pathways associated with the production of short-chain fatty acids (SCFAs), aromatic compound degradation, and mycobacterial metabolism vs. nTBs (red dotted line represents adjusted *p*-value=0.05; circle size represents relative abundance; pathways of interest are bolded). dTB: definite tuberculous pericarditis; PF: pericardial fluid; nTB: non-tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis; SCFA: short chain fatty acids.

618

Figure 6: Microbial composition differs in presumptive TBP people with high vs lowCRP.

621	A) CRP levels are similar in dTBs vs. pTBs vs. nTBs. B) Mycobacterial reads do not
622	correlate with CRP levels; \boldsymbol{r}_{s} represents the Spearman's Rho coefficient for the correlation of
623	mycobacterial reads with CRP. People with high CRP levels have similar C) Mycobacterium
624	reads and \boldsymbol{D}) $\alpha\text{-diversity}$ in their pericardial fluid compared to people with low CRP levels
625	(solid circles: dTB; empty squares: pTB; empty circles: nTB). E) β -diversity differs between
626	people with high vs low CRP. F) Pseudomonas is depleted in people with high vs low CRP.
627	Discriminatory taxa appear above the threshold (red dotted line, FDR=0.2); circle size
628	represents relative abundance. CI, Confidence interval; CRP, C-reactive protein; dTB:
629	definite-TBP; FDR, false discovery rate; nTBP, non-TBP; PERMANOVA, permutational
630	multivariate analysis of variance; pTB: probable-TBP; TBP: tuberculous pericarditis.

Figure 1.



Samples from 140 people were randomly rarefied to a depth of 1821 features and one sample with insufficient depth was excluded, leaving samples from 139 people.

Abbreviations: ART: antiretroviral therapy; dTB: definite tuberculous pericarditis; MGIT960 culture: mycobacteria growth indicator tube 960 liquid culture; nTB: non-tuberculous pericarditis; pTB: probable tuberculous pericarditis; Smear: Smear microscopy; Ultra: Xpert MTB/RIF Ultra; Xpert: Xpert MTB/RIF; TB: tuberculous;; TBP: tuberculous pericarditis.





Figure 3.



Figure 4.



Chest X-ray abnormalities

Effect size: log2(fold-change)

Figure 5.



Figure 6.

